Patient preparation for cardiac fluorine-18 fluorodeoxyglucose positron emission tomography imaging of inflammation

Journal of Nuclear Cardiology

Volumn 24, Issue 1, 2017, Pages 86-99

  Osborne, Michael T ^a,b   Hulten, Edward A ^c   Murthy, Venkatesh L ^d,e   Skali, Hicham ^b   Taqueti, Viviany R ^b   Dorbala, Sharmila ^b   DiCarli, Marcelo F ^b   Blankstein, Ron ^b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c WALTER REED ARMY MEDICAL CENTER   (United States)

^d UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^e UNIVERSITY OF MICHIGAN   (United States)

Author keywords

fluorodeoxyglucose (FDG); inflammation; metabolism; PET imaging

Indexed keywords

FATTY ACID; FLUORODEOXYGLUCOSE F 18; GLUCOSE; INSULIN; RADIOPHARMACEUTICAL AGENT;

ARTICLE; BEHAVIOR; CARDIAC IMAGING; DRUG UPTAKE; FOOD INTAKE; HEART MUSCLE METABOLISM; HUMAN; LIPID DIET; META ANALYSIS (TOPIC); PATIENT CARE; PATIENT PREPARATION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SARCOIDOSIS; DIAGNOSTIC IMAGING; DIET RESTRICTION; IMAGE ENHANCEMENT; LOW CARBOHYDRATE DIET; MYOCARDITIS; PROCEDURES; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; STANDARDS;

CARDIAC IMAGING TECHNIQUES; DIET, CARBOHYDRATE-RESTRICTED; FASTING; FLUORODEOXYGLUCOSE F18; HUMANS; IMAGE ENHANCEMENT; MYOCARDITIS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 84976272615     PISSN: 10713581     EISSN: 15326551     Source Type: Journal    
DOI: 10.1007/s12350-016-0502-7     Document Type: Article

References (33)

1. Blankstein R, Lundbye J, Heller G. Proceedings of the ASNC cardiac PET summit meeting, May 12 2014, Baltimore MD. J Nucl Cardiol 2015;22:720–9.
2. Cautela J, Alessandrini S, Cammilleri S, Giorgi R, Richet H, Casalta JP, et al. Diagnostic yield of FDG positron-emission tomography/computed tomography in patients with CEID infection: A pilot study. Europace 2013;15:252–7.
3. Saby L, Laas O, Habib G, Cammilleri S, Mancini J, Tessonnier L, et al. Positron emission tomography/computed tomography for diagnosis of prosthetic valve endocarditis: Increased valvular 18F-fluorodeoxyglucose uptake as a novel major criterion. J Am Coll Cardiol 2013;61:2374–82.
4. Blankstein R, Osborne M, Naya M, Waller A, Kim CK, Murthy VL, et al. Cardiac positron emission tomography enhances prognostic assessments of patients with suspected cardiac sarcoidosis. J Am Coll Cardiol 2014;21:166–74.
5. Morooka M, Moroi M, Ito K, Wu J, Nakagawa T, Kubota K, et al. Long fasting is effective in inhibiting physiological myocardial 18F-FDG uptake and for evaluating active lesion of cardiac sarcoidosis. EJNMMI Res 2014;4:1.
6. 18F-fluorodeoxyglucose (FDG) uptake and possible minimal effects of unfractionated heparin use in patients with suspected cardiac involvement sarcoidosis. J Nucl Cardiol 2016;23:244–52.
7. Demeure F, Hanin FX, Bol A, Vincent MF, Pouleur AC, Gerber B, et al. A randomized trial on the optimization of 18F-FDG myocardial uptake suppression: Implications for vulnerable coronary plaque imaging. J Nucl Med 2014;55:1629–35.
8. Wykrzykowska J, Lehman S, Williams G, Parker JA, Palmer MR, Varkey S, et al. Imaging of inflamed and vulnerable plaque in coronary arteries with 18F-FDG PET/CT in patients with suppression of myocardial uptake using a low-carbohydrate, high-fat preparation. J Nucl Med 2009;50:563–8.
9. Depre C, Vanoverschelde JL, Taegtmeyer H. Glucose for the heart. Circulation 1999;99:578–88.
10. Mochizuki T, Tsukamoto E, Kuge Y, Kanegae K, Zhao S, Hikosaka K, et al. FDG uptake and glucose transporter subtype expressions in experimental tumor and inflammation models. J Nucl Med 2001;42:1551–5.
11. Nuutila P, Koivisto VA, Knuuti J, Ruotsalainen U, Teras M, Haaparanta M, et al. Glucose-free fatty acid cycle operates in heart and skeletal muscle in vivo. J Clin Invest 1992;89:1767–74.
12. Yamada S, Kubota K, Kubota K, Ido T, Tamahashi N. High accumulation of fluorine-18-fluorodeoxyglucose in turpentine-induced inflammatory tissue. J Nucl Med 1995;36:1301–6.
13. Miyagawa M, Yokoyama R, Nishiyama Y, Ogimoto A, Higaki J, Mochizuki T. Positron emission tomography-computed tomography for imaging inflammatory cardiovascular disease Circ J. 2014;78:1302–10.
14. Bax JJ, Veening MA, Visser FC, van Lingen A, Heine RJ, Cornel JH, et al. Optimal metabolic conditions during fluorine-18 fluorodeoxyglucose imaging; A comparative study using different protocols. Eur J Nucl Med 1997;24:35–41.
15. Garfein O. Current concepts in cardiovascular physiology. Burlington: Elsevier Science; 2012. p. 565.
16. 18F-FDG PET in cardiac sarcoidosis: a systematic review and meta-analysis. Clin Nuc Med 2015. doi:10.1097/RLU.0000000000001063.
17. Harisankar CN, Mittal BR, Agarwal KL, Abrar ML, Bhattacharya A. Utility of high fat and low carbohydrate diet in suppressing myocardial FDG Uptake. J Nucl Cardiol 2011;18:926–36.
18. Soussan M, Brilley PY, Nunes H, Pop G, Ouvrier MJ, Naggara N, et al. Clinical value of a high-fat and low-carbohydrate diet before FDG-PET/CT for evaluation of patients with suspected cardiac sarcoidosis. J Nucl Cardiol 2013;20:120–7.
19. Cheng VY, Slomka PJ, Ahlen M, Thomson LE, Waxman AD, Berman DS. Impact of carbohydrate restriction with and without fatty acid loading on myocardial 18F-FDG uptake during PET: A randomized controlled trial. J Nucl Cardiol 2010;17:286–91.
20. 18F-fluorodeoxyglucose uptake using 24-h carbohydrate restriction and a low-carbohydrate, high-fat diet. J Cardiol 2013;62:314–9.
21. Balink H, Hut E, Pol T, Flokstra FJ, Roef M. Suppression of 18F-FDG myocardial uptake using a fat-allowed, carbohydrate-restricted diet. J Nucl Med Technol 2011;39:185–9.
22. Kumar P, Patel CD, Singla S, Malhotra A. Effect of duration of fasting and diet on the myocardial uptake of fluoro-2-deoxyglucose (F-18 FDG) at rest. Indian J Nucl Med 2014;29:140–5.
23. Coulden R, Chung P, Sonnex E, Ibrahim Q, Maguire C, Abele J. Suppression of myocardial 18F-FDG uptake with a preparatory “Atkins-style” low-carbohydrate diet. Eur Radiol 2012;22:2221–8.
24. 18F-FDG-PET imaging. J Nucl Med 2016;57:568–73.
25. Lum DP, Wandell S, Ko J, Koel MN. Reduction of myocardial 2-deoxy-2[18F]fluoro-d-glucose uptake artifacts in positron emission tomography using dietary carbohydrate restriction. Mol Imaging Biol 2002;4:232–7.
26. Lee HY, Nam HY, Shin SK. Comparison of myocardial F-18 uptake between overnight and non-overnight fasting in non-diabetic healthy subjects. Jpn J Radiol 2015;33:385–91.
27. Asmal AC, Leary WP, Thandroyen F, Botha J, Wattrus S. A dose-response study of the anticoagulant and lipolytic activities of heparin in normal subjects. Br J Clin Pharmacol 1979;7:531–3.
28. Gaeta C, Fernández Y, Pavía J, et al. Reduced myocardial 18F-FDG uptake after calcium channel blocker administration: Initial observation for a potential new method to improve plaque detection. Eur J Nucl Med Mol Imaging 2011;38:2018–24.
29. Japanese Society of Sarcoidosis and Other Granulomatous Disorders. Diagnostic standard and guideline for sarcoidosis. Tokyo: Japanese Ministry of Health, Labour and Welfare; 2006. p. 6.
30. Soejima K, Yada H. The work-up and management of patients with apparent or subclinical cardiac sarcoidosis: With emphasis on the associated heart rhythm abnormalities. J Cardiovasc Electrophysiol 2009;20:578–83.
31. Patel MR, Cawley PC, Heitner JF, Klem I, Parker MA, Jaroudi WA, et al. Detection of myocardial damage in patients with sarcoidosis. Circulation 2009;120:1969–77.
32. Dorbala S, Di Carli MF, Delbeke D, Abbara S, DePuey EG, Dilsizian V, et al. SNMMI/ASNC/SCCT guideline for cardiac SPECT/CT and PET/CT 1.0. J Nucl Med 2013;54:1485–507.
33. Vik-Mo H, Mjøs OD. Influence of free fatty acids on myocardial oxygen consumption and ischemic injury. Am J Cardiol 1981;2:361–5.